AUROBAC THERAPEUTICS APPOINTS SCIENTIFIC ADVISORY BOARD
The newly formed Scientific Advisory Board chaired by Dr. Marco Taglietti will provide technical and strategic guidance to support AUROBAC’s...
Antimicrobial
Canopy expands real-time wearable safety from hospitals to home health
Leading health systems expand staff safety initiatives by deploying Canopy's real-time support network beyond hospital walls PALO ALTO, Calif., June...
Recce Pharmaceuticals Completes Dosing Additional Cohort in Phase I/II UTI/Urosepsis Rapid Infusion Trial
Six additional participants intravenously dosed with RECCE® 327 (R327) at 4,000mg over 20 minutes – highest dosage to date in...
Osteal Therapeutics Closes $50M Series D Financing to Support Approval and Commercial Launch of Lead Candidate
Financing led by Zimmer Biomet with participation from existing investors Johnson & Johnson Innovation – JJDC, Inc., Gideon Strategic Partners,...
AUROBAC THERAPEUTICS Presents its R&D Strategy & Pipeline and Announces New Development Program in Partnership with Boehringer Ingelheim
AUROBAC THERAPEUTICS to advance ATX101 in septic shock, and multiple preclinical and discovery programs targeting Gram-negative pathogens. Lyon (France), June...
SciSparc Secures Strategic Advantage with Grant of European Patent
TEL AVIV, Israel, May 31, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical...
Immuron Board Changes
MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated...
Immuron CEO Steven Lydeamore to present at Peak Sky High
MELBOURNE, Australia, May 31, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated...
Cidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 Conference
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform...
Lift BioSciences Announces Abstract Publications at the American Society of Clinical Oncology (ASCO) Annual Meeting
Lift BioSciences Announces Abstract Publications at the American Society of Clinical Oncology (ASCO) Annual Meeting London, 24 May 2024 –...
CBIH Engages Prestigious Law Firm for its First Patent Applications
Houston, Texas--(Newsfile Corp. - May 20, 2024) - Cannabis Bioscience International Holdings(OTC Pink: CBIH), utilizing robust methodologies to safeguard its...
Covalon Presents Compassionate Care Technology at the Infusion Nurses Society (INS) Annual Meeting & Exhibition in Kansas City, MO
Visit Covalon at booth 420 to discover the latest in compassionate vascular access solutionsMISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company"...
Recce Pharmaceuticals Doses First Participants in Next Cohort of Phase I/II Urinary Tract Infections and Urosepsis Rapid Infusion Clinical Trial
First participants (male/female) dosed at 4,000mg over 20 minutes, with remaining subjects to be dosed in the near future -...
Provectus Biopharmaceuticals Announces Eight Presentations of Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2024 Annual Meeting
PDAT clinical outcomes for infectious keratitis from Brazil and Mexico KNOXVILLE, TN, May 14, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals,...
Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 in Lung Infection Pilot Study
RECCE® 327 (R327) demonstrated >99% log reduction (>2.5 log reduction) in Mycobacterium abscessus lung infections using a nebulizer delivery methodR327...
Salix Pharmaceuticals announces Bellamy Young as Spokesperson for Xifaxan(R) (rifaximin)
Xifaxan is the first and only FDA approved medication for the reduction in risk of OHE recurrence in adultsOvert Hepatic...
Salix Pharmaceuticals announces Bellamy Young as Spokesperson for Xifaxan(R) (rifaximin)
Xifaxan is the first and only FDA approved medication for the reduction in risk of OHE recurrence in adultsOvert Hepatic...
Four Groundbreaking Studies From NGS Pioneers MicroGenDX Were Presented for the First Time to Attendees of the Wound Healing Society 2024
Findings From These Studies Could Save Thousands of Lives Through Better Understanding the Mechanistic Basis of Chronic Wound InfectionORLANDO, FL...
In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy
Studies in neutropenic mouse model demonstrate prolonged and enhanced survival, reduced fungal burden and improvement in lung infectionBEDMINSTER, N.J., April...
Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
First-Ever Open IND for Prime Editing Technology PM359 is Prime Medicine’s Ex Vivo Product Candidate Designed to Correct a Prevalent...